February 12, 2019, Lyon (France)

A new step forward for EDELRIS with state‐of‐the‐art laboratories in BioParc Lyon.

Lyon is not only the “gastronomic center of France,” but also a hotspot and vibrant location for multiple pharma and biotech companies and public institutes and hospitals (over 58,000 employees in the LifeScience sector, including 6,800 in research). This year, a new biotech site (BioParc) will be added to the scientific map of Lyon. Edelris is happy to be part of this new investment.

The overall site is dedicated to life sciences and IT companies. The BioParc is going to be located on 3.4 hectares and will include 40,000 m 2 of high‐tech buildings for a total investment of €100 million. The site will accommodate 1000 employees and is ideally located in the heart of the hospital and academic research district in Lyon.

One of the buildings of the site, named BioSerra, will host Edelris, along with HQ offices and laboratories of several other biotech companies. In total, over 200 research scientists from Edelris, Erytech, Enyo Pharma, and ABScience will occupy the three wings of the building.

Jean‐Yves Ortholand (CEO of Edelris) says, “We have been based at the Lacassagne site (formerly a Merck R&D site) since our inception and later expanding into the Lyon‐South site. Both have been great facilities for us, but we have reached the point where it is time to reconvene into brand new, state‐of‐the‐art labs. BioSerra was an opportunity we could not miss, and we are now looking forward to moving into this new space within a few months”.

More news

{"acf_fc_layout":"postList","postList_model":{"ID":3651,"post_author":"5","post_date":"2023-09-05 09:18:27","post_date_gmt":"2023-09-05 07:18:27","post_content":"","post_title":"More news","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"more-news","to_ping":"","pinged":"","post_modified":"2023-11-20 08:54:07","post_modified_gmt":"2023-11-20 07:54:07","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.edelris.com\/?post_type=waz_post_template&p=3651","menu_order":35,"post_type":"waz_post_template","post_mime_type":"","comment_count":"0","filter":"raw"},"postList_post_type":"actualites","postList_category_post":false,"postList_category_actualites":false,"postList_nb_item_per_line":"postList_2_item","postList_nb_max_item":"2","postList_order_by":"none","postList_order_date_which":"acf","postList_order_date_elements":"future","postList_order_date_ordering":"ASC","postList_set_link":true,"postList_link_waz_popup":true,"postList_category_navigation":false,"postList_rub_nav_dropdown":false,"postList_rub_nav_position":"left","postList_rub_nav_all":"Tous les articles","postList_pagination":false,"postList_pagination_nb_posts":12,"postList_pagination_btn_model":false,"postList_pagination_text":"","options":{"animation":false,"animation_delay":0,"animation_element_delay":100,"margin_bottom":"","postList_id":""},"postList_limit_title":"","postList_limit_subtitle":"","postList_limit_description":"","postList_limit_break":"word","postList_limit_add_to_end":"","postList_use_custom_post_type":false,"postList_custom_post_type":"","postList_custom_taxonomy":"","postList_custom_toxonomy_values":"","postList_custom_title":"","postList_custom_subtitle":"","postList_custom_description":"","postList_custom_date":""}

About Edelris

Our DNA

Edelris has continuously been bringing creative solutions to clients and partners from drug discovery organizations for the past 17 years, with a clear focus on Hit generation and Hit-to-Lead optimization. Edelris has pioneered the value of 3D, natural productlike compound collections for HTS and FBLD (Keymical Collections™ and Fragments), and offers successful medicinal chemistry and synthesis of explorative chemical libraries, encoded and non-encoded. Further to this, Edelris differentiates itself with EDEN (Edelris Discovery ENgine) based upon a 2 million proprietary compound collection (Keymical Space™) and AS-MS technologies.

More info at www.edelris.com and LinkedIn.